US Patent

US11850221 — Ophthalmic pharmaceutical compositions and uses thereof

Method of Use · Assigned to Aerie Pharmaceuticals Inc · Expires 2042-12-16 · 17y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects ophthalmic pharmaceutical compositions containing WS-12 for treating, preventing, or ameliorating dry eye in a subject.

USPTO Abstract

Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, effectively reducing the likelihood of dry eye in a subject in need thereof, or for treating, preventing, or ameliorating signs or symptoms of dry eye in a subject in need thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1900 — Tryptyr

Patent Metadata

Patent number
US11850221
Jurisdiction
US
Classification
Method of Use
Expires
2042-12-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Aerie Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.